A 40-year-old man with a long history of chronic nasal obstruction was referred to our hospital. The obstruction had been caused when he sustained nasal trauma 5 years earlier. In addition to breathing difficulty, the obstruction had caused sleep disturbance. The patient had frequently taken medications for relief of the obstruction, but he did not improve.
Nasal endoscopy revealed a severe deviation of the nasal septum to the right and hypertrophy of the left inferior turbinate. An allergic skin test was negative. The patient's medical history was unremarkable, and he had not recently taken any anticoagulant or salicylate medication. Findings on hematologic, biochemical, and coagulation testing were normal.
The patient underwent septoplasty and Coblation of the left inferior turbinate under general anesthesia. Despite nasal packing with several pieces of Vaseline gauze, he experienced massive epistaxis during the evening of the day of surgery. When we attempted to insert some more pieces of Vaseline gauze in the outpatient clinic, the patient experienced a brief period of syncope secondary to sudden transient hypotension.
The epistaxis persisted after the syncope had resolved. The patient was returned to the operating room, and we controlled the bleeding with a suction coagulator without nasal packing. The source of the bleeding was identified as the posterior portion of the right inferior meatus. Soon after the epistaxis resolved, the patient reported a slight hearing loss and a feeling of fullness in both "Most insured pati ent s w ill pay no more th an S17 mon thly with a maximum benefit of SSO per fill. Restri ctions apply and co-pay amoun ts may vary. See program rules and eligi bi lity at w w w.ZETONNA.com
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Immunosuppression
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DRUG INTERACTIONS
In vitro studies and clinical pharmacology studies suggested that desciclesonide has no potential formetabolic drug interactions orprotein binding- The safety and effectiveness forseasonal and perennial allergic rhinitis in children 12years ofage and older have been established. The safety and efficacy ofZETONNA Nasal Aerosol fortreatment ofthe symptoms of seasonal and perennial allergic rhinitis in patients 11 years of age and younger have not been established.
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Continuedfrom page350
ears. Otoscopy detected bilateral red-blue tympanic membranes (figure). Tympanometry yielded a type B (flat) result in both ears. Audiometry demonstrated mild bilateral conductive hearing loss. At follow-up 3 weeks later, otoscopy revealed that both tympanic membranes were mobile and normal in appearance. Audiometric evaluation showed hearing had returned to previous levels, and tympanometric findings were normal (type A). Hemotympanum has many causes, including temporal bone fractures, barotrauma, administration of anticoagulants, hematologic disorders, and chronic otitis media secondary to the formation of granulation tissue or a cholesterol granuloma.I Hemotympanum secondary to nasal packing or spontaneous epistaxis has also been reported.':' Moreover, eustachian tube dysfunction has been proposed as a cause of this condition, with perituballymphatic stasis representing the most likely pathogenic mechanism.' 354 " www.entjournal.com
In cases of epistaxis with or without nasal packing, blood can reflux into the middle ear via a patulous eustachian tube. Treatment ofhemotympanum is usually conservative. Myringotomy and insertion of a ventilation tube may be needed for treatment when the condition persists beyond 1 month.' Most cases ofhemotympanum resolve with no sequelae.
